Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss
A potential minor treatment benefit is suggested by the statistically significant, small attenuation of worsening work loss following fatigue treatment initiation compared with untreated people with MS. No differences in treatment benefit were observed across fatigue treatments.
Authors
- Simon Englund (ORCID: https://orcid.org/0000-0002-1042-4400)
- Thomas Frisell (ORCID: https://orcid.org/0000-0002-5735-9626)
- Johan Reutfors (ORCID: https://orcid.org/0000-0003-1372-4262)
- Fredrik Piehl (ORCID: https://orcid.org/0000-0001-8329-5219)
Institutions
- Karolinska Institutet (SE)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1002/acn3.70259
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vetenskapsrådet